Checkpoint Therapeutics, Inc.
(NASDAQ : CKPT)

( )
CKPT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
0.50%147.230.6%$1189.34m
MRKMerck & Co., Inc.
1.19%78.030.6%$1026.59m
PFEPfizer Inc.
0.36%44.170.9%$1005.85m
ABBVAbbVie, Inc.
0.51%88.622.2%$564.83m
LLYEli Lilly and Company
-0.11%114.371.0%$515.63m
BMYBristol-Myers Squibb Company
2.00%53.481.4%$473.92m
NVSNovartis AG Sponsored ADR
1.07%88.150.2%$230.45m
AZNAstraZeneca PLC Sponsored ADR
0.65%38.911.3%$213.76m
GSKGlaxoSmithKline plc Sponsored ADR
0.83%37.670.2%$149.91m
NVONovo Nordisk A/S Sponsored ADR Class B
1.77%46.000.1%$65.94m
SNYSanofi Sponsored ADR
1.85%45.140.2%$46.70m
LCILannett Company, Inc.
-0.19%5.2637.0%$9.76m
AKTXAkari Therapeutics Plc Sponsored ADR
-0.84%1.801.7%$0.03m
EPIXESSA Pharma Inc
1.60%2.540.1%$0.00m

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX). It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP). The company was founded on November 10, 2014 and is headquartered in New York, NY.